Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alfresa, CMIC Ink Pact to Build Vaccination Support Platform
Japanese drug wholesaler Alfresa Holdings and CMIC Holdings, a provider of CRO/CDMO and other healthcare-related services, said on December 2 that they have agreed to collaborate toward establishing a comprehensive vaccination support platform in Japan. Alfresa Holdings’ core unit Alfresa…
To read the full story
BUSINESS
- Kyowa Kirin Keeps Long-Term KPIs despite OX40 Setback, Ups 2026 Core Profit Outlook
May 11, 2026
- Onychomycosis Drug Jublia Now Available in Germany: Kaken
May 11, 2026
- Fujifilm Bags Japan Approval for Meniscus Regenerative Therapy
May 11, 2026
- Takeda Logs Positive PII/III Results for TAK-881 in PID, Eyes FY2026 Filing
May 11, 2026
- Capricor Sues Nippon Shinyaku over US Rights to DMD Cell Therapy
May 11, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…